

general indictment of the industry or the profession or that the Congress feels that that industry or profession or economic or social group is not making a very fine contribution to society.

I have introduced a fair amount of consumer legislation involving pesticides and the chemical industry, the tire industry, tire safety standards, the auto industry, and a number of others. I remember when I introduced the tire and auto safety bills, I was attacked in some quarters as being against the auto industry, which it could be said is the greatest, at least in terms of its size, of any industry in the country. I had to point out repeatedly that the fact that I thought there were some things wrong in that industry in terms of the work they are doing in safety, and in terms of the quality of tires the auto industry was using, this is not a general indictment of the industry.

There is not any group in the country that has a relationship with the public that is perfect. The purpose of this hearing is to raise issues in which the public has an interest. The problems and issues raised before this committee have not been raised by the members, by me, or the members of the committee. They have been raised by witnesses who come before the committee, and, like anybody else, I could agree with some and disagree with others, based upon what they have to say.

But in the last 2 years there have been a large number of very reputable witnesses who have been critical of certain practices in the medical profession, of the medical journals, and of the drug industry. They have been very distinguished men who have been willing to come before the committee and express their opinions about these various matters.

Of course, there have been others who have come before the committee to respond or to criticize those who have criticized. We have made it a point in this committee, which I think we must, to be fair, when we are discussing anything involving the drug industry, and that has been the main thrust of these hearings, that any company that was criticized would have an opportunity forthwith to respond to that criticism and whenever they have asked for the opportunity, we have set up the earliest possible date in order to let them respond to anything that was said before the committee.

We also have made it the policy of this committee to hear from all viewpoints respecting any issues raised. And we have been trying to do that. We cannot hear from everybody at once, of course, because we would have to hold the hearing in a stadium.

But anyway, the fact that these questions are raised before the committee, as you well appreciate, puts me in an adversary position, in the view of many, since that is the kind of issue that is being raised here. In other words, it is a hearing to raise public questions of importance which are critical of certain practices in the drug industry.

Many times, it has been said, "Well, you are just hearing the bad things about the drug industry." Well, we know a great deal about the good things. However, that is why we have always been happy to permit the drug industry or the Pharmaceutical Manufacturers Association to appear, or anybody else, and delineate in a great detail as they desire the contributions, the work of the particular organization they represent.

While we will be pleased to have your summary of the vast amount of work the American Medical Association does—I realize it is, just